tbuckley/cabot-search huggingface dataset:
Efficacy of alemtuzumab (ALZ) in combination with dose-adjusted EPOCH (DA-EPOCH) in untreated nodal peripheral T-cell lymphoma (PTCL).
Authors: Cliona Grant, Kieron Dunleavy, John E. Janik, Margaret Shovlin, Seth M. Steinberg, Francesco D'Amore, Maryalice Stetler-Stevenson, Stefania Pittaluga, Elaine S. Jaffe, Wyndham Hopkins Wilson
Journal: Journal of Clinical Oncology (2012)

8051 Background: The survival of patients (pts) with PTCL (excluding ALCL) is disappointing following anthracycline-based therapy and novel approaches are needed. In diffuse large B-cell lymphoma, the addition of anti-CD20 therapy to CHOP has significantly improved outcome and we investigated if in PTCL, adding ALZ – which targets CD52, expressed on most PTCLs – was feasible and improved outcome. Methods: This was a single-center phase I/II trial of ALZ, in combination with DA-EPOCH in patients with treatment-naïve CD52+ PTCL. The MTD of 30 mg ALZ was combined with DA-EPOCH for phase II evaluation resulting in an intention-to-treat population (ITTP) of 30 pts. Results: Patient (n=30) characteristics: median (range) age 50 (17-77); M:F 1:1; Stage III/IV 27 (90%); IPI ≥2 22 (73%). Histologies: ATLL 11 (37%), PTCL NOS 6 (20%), AITL 5 (16%), Hepatosplenic 3 (10%), Peripheral T NK cell 2 (7%), Other 3 (10%). At 67 months median follow-up, 11 patients were alive, 10 disease-free. Median overall (OS) and event-free survivals (EFS) were 15.4 and 6.7 months respectively. Outcome was substantially better for pts with ‘nodal’ (AITL, PTCL-NOS, Other) compared to ‘non-nodal’ (ATLL and ‘extranodal’ histologies) PTCL subtypes. 3-year OS for the two groups was 58.3% and 27.8% respectively (p=0.082); 3-yrs EFS was 50% (median 27.0 months) and 22.2% (median: 5 months) respectively (p=0.041). Half of the ‘nodal’ PTCL pts had sustained long-term complete remissions demonstrated by a plateau in the EFS curve at 27 months. There were 3 treatment related deaths: 2 from neutropenic sepsis; 1 from toxoplasma. Other toxicities included CMV and BK virus reactivation in 53% and 30% respectively. Febrile neutropenia was seen in 20% and grade 4 thrombocytopenia in 12 % of cycles. Conclusions: Although it has significant infectious toxicity, ALZ 30mg and DA-EPOCHin untreated PTCL is feasible and associated with a long-term favorable outcome in nodal but not extranodal or leukemic PTCL. A phase III study of ALZ 30mg with anthracycline-based therapy is ongoing and we await the results with interest.
Abstract 12979: Pulse Pressure Variation Predicts Mortality After Acute Myocardial Infarction
Authors: Georg Schmidt, Petra Barthel, Alexander Muller, Simon Schneider, Nadine Junk, Marek Malik
Journal: Circulation (2010)

Increased pulse pressure (PP) is associated with increased risk of cardiovascular events, however, little is known about PP beat-to-beat variation. Aim of this study was to assess PP variation and its association with mortality in post-infarction patients. Methods: Prospective inclusion of 938 consecutive post-infarction patients in sinus rhythm aged <=80 years. Non-invasive 30-min recordings of arterial pressure (Portapres) 7 ± 2 days after index infarction. Quantification of PP variation by PP standard deviation (PPSD), and PP phase rectification (PPPR) assessed by modified phase-rectified signal averaging. Figure shows PPPR examples. Follow-up period was 5 years. Primary endpoint was total mortality. Results: During follow-up, 61 patients (6.5%) died. Mortality was strongly correlated with PPPR (p<0.0001) and moderately correlated with PPSD (p<0.05) .High values of PPSD and PPPR indicated increased mortality risk. In multivariable Cox regression adjusted for known risk predictors (age, history of a pre...
GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort
Authors: Neven Tudoric, Vladimir Koblizek, Marc Miravitlles, Arschang Valipour, Branislava Milenkovic, Adam Barczyk, Attila Somfay, Kirill Zykov, Kosta Kostov, Zuzana Zbozinkova, Michal Svoboda, Jurij Sorli, Alvils Krams, Ruzena Tkacova
Journal: European Respiratory Journal (2017)

Recently, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) released a revised consensus report (2017 GOLD Report) [1] in which the formerly defined ABCD classification of patients with COPD has been refined. The 2011 GOLD Report and its 2016 Update classified patients on the basis of three variables, i.e. the symptom burden, lung function impairment and exacerbations [2], now the A–D groups are defined solely on the basis of symptoms and history of exacerbations – thus recognising the limitations of the forced expiratory volume in 1 s (FEV1) in influencing therapeutic decisions in COPD [1]. The obvious consequence of the new classification is a shift of a proportion of patients from the C to the A group, and from the D to the B group. Nevertheless, the magnitude of such redistribution remains unknown. The distribution of patients based on exacerbations solely is the most profound consequence of the 2017 GOLD Report <http://ow.ly/4UJa309fLbM>
Physician Charges and Medicare Payments
Authors: Jeffrey Plagenhoef
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparing Drivers and Dynamics of Tuberculosis in California, Florida, New York, and Texas
Authors: Sourya Shrestha, Andrew N. Hill, Suzanne M. Marks, David W. Dowdy
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

There is substantial state-to-state heterogeneity in tuberculosis (TB) in the United States; better understanding this heterogeneity can inform effective response to TB at the state level, the level at which most TB control efforts are coordinated.To characterize drivers of state-level heterogeneity in TB epidemiology in the four U.S. states that bear half the country's TB burden: California, Florida, New York, and Texas.We constructed an individual-based model of TB in the four U.S. states and calibrated the model to state-specific demographic and age- and nativity-stratified TB incidence data. We used the model to infer differences in natural history of TB and in future projections of TB.We found that differences in both demographic makeup (particularly the size and composition of the foreign-born population) and TB transmission dynamics contribute to state-level differences in TB epidemiology. The projected median annual rate of decline in TB incidence in the next decade was substantially higher in Texas (3.3%; 95% range, -5.6 to 10.9) than in California (1.7%; 95% range, -3.8 to 7.1), Florida (1.5%; 95% range, -7.4 to 14), and New York (1.9%; 95% range, -6.4 to 9.8). All scenarios projected a flattening of the decline in TB incidence by 2025 without additional resources or interventions.There is substantial state-level heterogeneity in TB epidemiology in the four states, which reflect both demographic factors and potential differences in the natural history of TB. These differences may inform resource allocation decisions in these states.
IgG Subtype Affects Immunomodulation through FcγRs, on Non-Macrophage Populations in a Murine Model - Mechanistic Implications for Anti-D
Authors: James C. Zimring, Hayley Waterman, Xiaohong Wang, Linda Kapp, Jenna Lebedev, Heather Howie, Ariel Hay, Tamara Carola Stegmann, Gestur Vidarsson, C. Ellen Van der Schoot
Journal: Blood (2016)
Novel DNA-Damaging Linker Payloads Are Active in Models of Acquired Resistance to Calicheamicin and Standard of Care
Authors: Jennifer Kahler, Maureen Dougher, Jia Lu, Jane Xu, Tasneem Kausar, Luanna Lemon, Wenyan Zhong, Judy Lucas, Matthew Sung, Puja Sapra
Journal: Blood (2016)
Knock-knock-knockin’ on bile duct’s door: the “tip-of-the-biopsy-forceps technique” – probing the route during freehand-intubated direct cholangioscopy
Authors: Vincent Zimmer
Journal: Endoscopy (2017)

Direct cholangioscopy is a highly innovative field in pancreaticobiliary endoscopy; however, its wider dissemination is hampered by high technical procedural demands and/or the need for specialized equipment. Much technological progress is underway including clinical evaluation of double-bending cholangioscopes and next-generation anchoring balloons [1] [2]. By contrast, freehand intubation for direct cholangioscopy has largely been discredited by expert opinion, even though high rates of technical success have been published in single series and individual clinical reports [3].
Dynamic analysis of HCV-RNA, TTV-DNA and transaminases serum levels in patients with chronic hepatitis: Evidence for occasional pathogenicity of TTV.
Authors: P Colombatto, F Maggi, F Oliveri, A Morrica, Am Maina, Ml Vatteroni, B Coco, Mauro Pistello, Ferruccio Bonino, M Bendinelli, Maurizia Rossana Brunetto
Journal: Hepatology (1999)
Who Is Responsible for the Safe Introduction of New Surgical Technology?
Authors: Jason C. Pradarelli, Joseph P. Thornton, Justin B. Dimick
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Association between air pollution and ventricular arrhythmias in high-risk patients (ARIA study): a multicentre longitudinal study
Authors: Franco Folino, Gianfranco Buja, Gabriele Zanotto, Elena Marras, Giuseppe Allocca, Diego Vaccari, Gianni Gasparini, Emanuele Bertaglia, Franco Zoppo, Vittorio Calzolari, Rene Nangah Suh, Barbara Ignatiuk, Corrado Lanera, Alessandro Benassi, Dario Gregori, Sabino Iliceto
Journal: The Lancet Planetary Health (2017)

BackgroundAlthough the effects of air pollution on mortality have been clearly shown in many epidemiological and observational studies, the pro-arrhythmic effects remain unknown. We aimed to assess the short-term effects of air pollution on ventricular arrhythmias in a population of high-risk patients with implantable cardioverter-defibrillators (ICDs) or cardiac resynchronisation therapy defibrillators (ICD-CRT).MethodsIn this prospective multicentre study, we assessed 281 patients (median age 71 years) across nine centres in the Veneto region of Italy. Episodes of ventricular tachycardia and ventricular fibrillation that were recorded by the diagnostic device were considered in this analysis. Concentrations of particulate matter of less than 10 μm (PM10) and less than 2·5 μm (PM2·5) in aerodynamic diameter, carbon monoxide, nitrogen dioxide, sulphur dioxide, and ozone were obtained daily from monitoring stations, and the 24 h median value was considered. Each patient was associated with exposure data from the monitoring station that was closest to their residence. Patients were followed up for 1 year and then scheduled to have a closing visit, within 1 more year. This study is registered with ClinicalTrials.gov, number NCT01723761.FindingsParticipants were enrolled from April 1, 2011, to Sept 30, 2012, and follow-ups (completed on April 5, 2014) ranged from 637 to 1177 days (median 652 days). The incidence of episodes of ventricular tachycardia and ventricular fibrillation correlated significantly with PM2·5 (p<0·0001) but not PM10. An analysis of ventricular fibrillation episodes alone showed a significant increase in risk of higher PM2·5 (p=0·002) and PM10 values (p=0·0057). None of the gaseous pollutants were significantly linked to the occurrence of ventricular tachycardia or ventricular fibrillation. In a subgroup analysis of patients with or without a previous myocardial infarction, only the first showed a significant association between particulate matter and episodes of ventricular tachycardia or ventricular fibrillation.InterpretationParticulate matter has acute pro-arrhythmic effects in a population of high-risk patients, which increase on exposure to fine particles and in patients who have experienced a previous myocardial infarction. The time sequence of the arrhythmic events suggests there is an underlying neurally mediated mechanism. From a clinical point of view, the results of our study should encourage physicians to also consider environmental risk when addressing the prevention of arrhythmic events, particularly in patients with coronary heart disease, advising them to avoid exposure to high levels of fine particulate matter.FundingThere was no funding source for this study.
A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date
Authors: Daniel J. DeAngelo, Jane L. Liesveld, Brian A Jonas, Michael E O'Dwyer, Dale L. Bixby, John L Magnani, Helen M. Thackray, Pamela S. Becker
Journal: Blood (2016)
Gemcitabine-oxaliplatin (GemOx) combination followed by chemoradiotherapy (CRT) in borderline pancreatic adenocarcinoma (BPC).
Authors: Olivia Hentic, Jerome Cros, Magaly Zappa, Vinciane Rebours, Safi Dokmak, Beatrice Aussilhou, Chantal Dreyer, Philippe Levy, Frederique Maire, Anne Couvelard, Alain Sauvanet, Philippe B. Ruszniewski, Pascal Hammel
Journal: Journal of Clinical Oncology (2014)

e15231 Background: Whereas BPC is potentially resectable, the risks of incomplete (R1) resection or early progression are high. Tumor response rate using GemOx in metastatic setting was of 27% with safety profile and CRT increase the rate of R0 resections. Aim: To evaluate feasibility and efficacy of a neoadjuvant therapy with GemOx+CRT in patients (pts) with BPC according to the MD Anderson classification. Methods: In this retrospective monocentric study, all eligible pts (PS<2, no contraindication for surgery) received 2 months of GemOx (gemcitabine 1000mg/m² D1, oxaliplatin 85 mg/m² D2, D1=D14); then, CRT (54 Gy+capecitabine) was administered in pts with tumor control. 2ndevaluation was done 1 month later to evaluate tumor resecability. Rate of treatment completion and resection, pathological response and disease free (DFS) and overall survival (OS) were analysed. Results: From 06/05 to 05/13, 72 pts (M= 38 [53%], median age 63 [42-80] yrs) received a median of 5[3-8] GemOx. After 1stevaluation, 17(24%) pts did not have CRT due to frontline surgery (n=8), progression (local n=2/metastatic n=5) or contraindication to CRT (n=2). Among the 55 (76%) pts receiving complete treatment, 29 (53%) had laparotomy and 26 did not undergo surgery mainly due to progression (n=20). After 6 [2-10] months, 37 pts had laparotomy and 34/72 (47%) had curative intent resection (Whipple n=25/left pancreatectomy n=9); in 3 other pts, metastases were found peroperatively. There was no death related to treatment or surgery. The pathological data were ypT1, T2 and T3 in 4, 2 and 28 (82%) pts/N0 and N1 in 18 (53%) and 16 pts/N1 in 16 and R0 in 32 (94%) pts. Pathological response according to intratumoral fibrosis was 1-50% and 51-100% in 18 and 16 pts Adjuvant chemotherapy was not proposed in 4 (12%) pts. After a median follow-up of 18 months [3-75], OS of the whole population was 25 months; in the 34 resected pts, it was of 51 months and 54% at 5 yrs with a DFS of 33 months. Conclusions: Among the 47% pts with resected BPC after a neoadjuvant GemOx combination followed by CRT, a R0 resection rate was achieved in 94% with an actuarial median OS of 51 months. This schedule should be tested in a prospective manner for BPC.
Downregulating ANP32A rescues synapse and memory loss via chromatin remodeling in Alzheimer model
Authors: Gao-Shang Chai, Qiong Feng, Zhi-Hao Wang, Yu Hu, Dong-Sheng Sun, Xiao-Guang Li, Dan Ke, Hong-Lian Li, Gong-Ping Liu, Jian-Zhi Wang
Journal: Molecular Neurodegeneration (2017)

The impairment of histone acetylation is causally linked to the cognitive decline in Alzheimer's disease (AD). In addition to histone acetyltransferases (HATs) and histone deacetylases (HDACs), inhibitor of acetyltransferases (INHAT) can also regulate histone acetylation. As a key component of INHAT, level of ANP32A is selectively upregulated in the brain of AD patients. Here we investigated whether downregulating ANP32A can rescue AD-like synapse and memory deficits.RFP-labeled lentiviral ANP32A-shRNA was infused stereotaxically into the hippocampal CA3 region of the human tau transgenic mice (termed htau). The spatial learning and memory were assessed by Morris water maze (MWM). The synaptic function was measured by electrophysiological recording and the spine density was detected by Golgi staining. RT-PCR and Western blotting were used to detect the mRNA and protein levels.Elevation of ANP32 in htau transgenic mice was correlated with learning deficits, while the hippocampal infusion of lenti-siANP32A to downregulate ANP32A in 12 m-old htau mice could rescue memory loss. Further studies demonstrated that downregulating ANP32A restored synapse morphology and the function. In the brain of htau mice, the acetylated histone decreased while knockdown ANP32A unmasked histone for a robust acetylation with reduced INHAT complex formation. Downregulating of ANP32A also attenuated AD-like tau hyperphosphorylation. Finally, several AD-associated risk factors, including tau accumulation, β-amyloid and H2O2 exposure, increased ANP32A by activating CCAAT/enhancer binding protein-β (C/EBPβ).We conclude that downregulating ANP32A rescues synaptic plasticity and memory ability by reducing INHAT formation and unmasking histone for hyperacetylation. Our findings reveal novel mechanisms for AD memory loss and potential molecular markers for protection.
Back to the History
Authors: Mary W. Montgomery, Sigal Yawetz, Bruce D. Levy, Joseph Loscalzo
Journal: New England Journal of Medicine (2017)

An 82-year-old man presented to the emergency department with a 6-month history of worsening back and left hip pain. The pain did not radiate down his legs, but it occasionally woke him from sleep, was worse after activity, and was not relieved by bending forward.
In Vivo Demonstration of PSMA Expression in Adenocarcinoma Urinary Bladder Using 68Ga-PSMA 11 PET/CT
Authors: Shambo Guha Roy, Girish Kumar Parida, Sarthak Tripathy, Abhinav Singhal, Madhavi Tripathi, Chandrasekhar Bal
Journal: Clinical Nuclear Medicine (2017)

In vitro and in vivo studies have demonstrated prostate-specific membrane antigen (PSMA) expression in various malignant and benign tumors. Based on the recent immunohistochemical study showing PSMA expression in adenocarcinoma of urinary bladder, we hypothesized that PSMA expression in adenocarcinoma of urinary bladder can be demonstrated in vivo using Ga-PSMA 11 PET/CT. We present a man with exstrophy bladder, presenting with adenocarcinoma urinary bladder referred for staging PET/CT. Both F-FDG and Ga-PSMA-11 PET/CT were done, which showed PSMA expression in the primary tumor as well as metastatic lymph nodes.
Role of Leaders in Fostering Meaningful Collaborations Between Academic Medical Centers and Industry While Also Managing Individual and Institutional Conflicts of Interest
Authors: Philip A. Pizzo, Thomas J. Lawley, Arthur H. Rubenstein
Journal: JAMA (2017)

This Viewpoint discusses the important role that leaders of academic medical centers (AMCs) play in fostering collaborations with industry while managing individual and institutional conflicts of interest (COI).
Phase I/IIa multicenter trial for high-risk and recurrent neuroblastoma: Anti-GD2 antibody (ch14.18) immunotherapies using M-CSF or G-CSF.
Authors: Hiroshi Kawamoto, Kenichi Yoshimura, Toshimi Kimura, Chika Nitani, Junichi Hara
Journal: Journal of Clinical Oncology (2014)

TPS10095 Background: Anti-GD2 antibody, ch14.18, with GM-CSF or IL2, has significantly improved disease free survival in high-risk neuroblastoma. ch14.18 generally induces cell lysis through the process of antibody-dependent Cellular Cytotoxicity (ADCC) through PBMC (NK cell etc.) as effector cell. Concurrent use of GM-CSF with ch14.18 enhances the effect of both neutrophils and PBMC mediated ADCC. To maximize ADCC, this phase I/IIa study was planned to optimize dosing and feasibility, and to evaluate ADCC in using M-CSF (R1) and G-CSF (R2). Methods: Eligibility: Patients (pts) aged between 2 and 45 years with refractory or relapsed (phase I and phase IIa) and high risk (phase IIa) neuroblastoma. Other important requirements were as follows: good PS; normal organ function; appropriate interval from prior antitumor therapies; no history of allogeneic hematopoietic stem cell transplantation; No intracranial hemorrhagic episode within one month if central nervous system metastasis exits. Treatment plan: In R1, CSF regimen (ch14.18 10-20h div d4-7, M-CSF 2h div d1-14) and IL2 regimen (ch14.18 10-20h div d8-11, IL2 24h div d1-4, d8-11) are alternately performed every one month, up to 5 courses with starting from CSF regimen. In R2, G-CSF s.c. is replaced with M-CSF in CSF regimen. Endpoints: Primary endpoint is DLT of ch14.18, IL2, M-CSF, G-CSF (phase I) and proportion of completing 5 courses of R1 and R2 (phase IIa). Secondary endpoints include pharmacokinetics and dose-response for ch14.18 and IL2, ADCC activity and anti-chimera antibody response proportion. Study design: Multi-center, phase I/IIa design. In phase I, ch14.18, M-CSF, G-CSF, IL2 are all object for dose finding by 3+3 design, with starting dose 17.5mg/m2 (level1), 6 million IU/m2 (level1), 5 ug/kg (level1), 0.75 million IU/m2(1 week) and 1 million IU/m2(2 week) (level0). In phase IIa, sixteen pts are required to confirm feasibility of optimized R1 and R2 regimens in phase I with a threshold for five month PFS of 31% and one-sided alpha level 5%. Clinical trial information: UMIN000012001.